Invitae CEO Sean George joins Yahoo Finances on the move to talk about how Invitae is bringing genetic testing and information into mainstream discussions.
JULIE HYMAN: Im watching shares of Invitae, which have just about tripled this year. We are joined now by the CEO, Sean George, from San Francisco. Sean, thanks for joining us. You guys do diagnostic testing and you dont do it for COVID specifically, but you do it for a host of other diseases. And weve obviously seen COVID-19 testing really expand. You can drive up and get it in places. There are now going to be at-home tests that are going to be introduced. Do you think that this then gets people more comfortable with testing for a range of different diseases? Or are you hoping that it does?
SEAN GEORGE: Well, I think it does. And I think in general, trend of the last decade or so is people are starting to understand that this diagnostic information is very useful in advance of when theres an actual problem. Obviously, people are now getting very familiar with COVID testing, what it could have done prior to, and certainly during an outbreak and to manage it.
And when you think about how fundamental in an individuals genomic information is for their health, the idea is starting to catch hold with more and more people, especially generalists, and the idea that genetic information used at the right time, ahead of time, at every stage in life, has profound implications on an individuals health.
ADAM SHAPIRO: So these kinds of tests, we keep hearing in relation to COVID, the issue of false positives. But putting that to the side, in the traditional diagnostic models, whats an accepted, if there is, metric, for when youre going to get a false positive or false negative? How does the industry deal with that issue?
SEAN GEORGE: Right, and especially in medical genetics, that threshold is very, very, very, very tight. Its exacting on 99 and a few nines of how the percentage of sensitivity and specificity these tests need to have because of the profound implications of genetics. Whether its dealing with cancer, cardiovascular disorders, pediatric disorders, battling cancer as 45 million people are per year in the markets we serve, and to answer those fundamental questions and then take concrete medical next steps. The sensitivity specificity, the precision of the tests need to be extraordinarily high.
Story continues
BRIAN CHEUNG: Hey, Sean, Brian Cheung here. So for those that maybe arent that well versed in this type of science, explain to us exactly where you fit in the business world of things that might be tangentially related to genetic testing. I mean, do you guys work with say CRISPR firms or types of, I guess, diagnostic or treatment relative to businesses in that space? Where does your business fit in that universe?
SEAN GEORGE: I think the way to think about it, the people who, certainly anybody who has had an introduction or a brush with genetics and the health care, their clinician, were the number one brand in medical genetics around the globe. Their clinician certainly knows us and has been working with us for many years. And again, whether thats to diagnose any number of 1,000 rare disorders, to help an individual understand their prognosis and next best steps for cancer treatment.
Certainly around reproductive health. You may have heard carrier screening or non-invasive prenatal screening. Those are the kind of tests that we do. And we primarily do it with your clinician. Certainly up until now, mostly the specialists of the world, the medical genetics, the various conditions. Like I said, there are thousands. Ever increasingly, as we have dramatically driven down the price of the, weve driven down the cost of this testing by almost two orders of magnitude over the last 10 years.
And ever increasingly, generalists are starting to use this information. Theyre becoming more comfortable with it. We have tools and front end capabilities to allow clinicians to use the information without the deepest of knowledge around each individual gene, around each individual condition. And have tools online to follow the patients, follow up on their results, make sure they understand what the next best step is, and really support the clinician, the patient with the use of genetics in mainstream medical care.
JULIE HYMAN: And Sean, when were talking about genetics testing, is it mostly probability testing, particularly for cancers when you talk about carrier testing that youre at X percent risk for developing a certain disorder? Or is genetics testing also increasingly being used for actual diagnosis?
SEAN GEORGE: The kind of testing we specialize, the kind of testing put into play by most clinicians, medical geneticists, is a little more precise than just a very slight probability increase over average risk. These are, carrier screens, you mentioned, this will tell you whether you and your partner are carrying different conditions. It will tell you what are the odds specifically of having a child who might be affected by the condition. Or if you were to have a child, what would the odds be.
Ill take, for example, some of the cardiovascular diseases or cancer genetic diseases. If you have some of these genes that are affected, your risk is 30 to 80 times the population average risk of these conditions. So its quite prognostic. Now like I said, when you do get an answer, it really helps to diagnose the condition far earlier than you would otherwise be able to without the use of genetics.
And then depending on the disease, there are a variety of next steps, all the way from preventive approaches to therapies. And we work with over 100 biopharmaceutical partners too, who have therapies that are specifically targeted against genetic conditions that we can introduce our patients to as early as possible.
JULIA LA ROCHE: Sean, this is such a fascinating discussion, what youve been bringing up, and youre talking about the next best action. And its such an interesting way to look at health care, especially looking at it from preventative as well, or even just having a better understanding of your genetics and what it could mean or what the outcomes can be. I guess for you, if we could just kind of step back, what is the moonshot for you when it comes to your business and the broader health care system?
SEAN GEORGE: And in fact, were kind of, Im not sure at what inning we are in of that moonshot, I think its probably early, first or second. But the real idea, and when we founded the company, it was a simple idea. Genetics is so impactful for health care on an individual basis, yet is sparingly used at all in modern health care around the globe. The moonshot is really to have an individuals genome available, managed on their behalf, so that information can be put into play at the right point, at the right time, with all of the people around them that can help put that information to use for their health.
So for example, upon birth. 3% of live births end up in the NICU or the PICU because of genetic conditions. Having that information instantaneously would dramatically improve the outcome of the children in that situation. Some 20% to 30% of populations primary health care complaint over their lives will be genetic in nature.
Knowing that ahead of time instead of after years and years and years of symptoms kind of popping up and then getting worse over time and finally getting diagnosed, knowing ahead of time can greatly improve the preventive measures taken. I think we will in five to 10 years, we will look back in horror thinking that women had children, started families without accessing the fundamental genetic information that can introduce so much risk along the way, either for the women themselves during carrying to term, and then certainly upon delivery.
And I think cancer is another example. Its one of the more advanced conditions when considering molecular medicine. I think again, in 10 years well look back, and the idea that we didnt access the fundamental information about a persons genetic background and the genomics of the cancer itself to precision tailor treatment to them, I think well look back and wonder why we didnt do it faster.
But again, a big problem with that has been cost in the past, and weve taken care of that and are continuing to work on it. So I think across all stages in life, were about to see here in the next decade this genetic information to be used almost as a medical utility. Again, and our aim is, the moonshot is to across all stages of life, all the way from birth until youre dealing with aging and senescence.
Read the rest here:
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]